ArticleNeuro-oncology2021

Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.

Kathleen M Schmainda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.